Last reviewed · How we verify
NCT06853158: MULTI-MUSIQOLS
MULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease
NA trial testing Music therapy in Sickle Cell Disease in 90 participants. Currently enrolling.
14 December 2026
Quick facts
| Lead sponsor | University of California, Irvine |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | other |
| Enrollment | 90 |
| Start date | 2 April 2025 |
| Primary completion | 14 December 2026 |
| Estimated completion | 31 January 2027 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Music therapy
- Health education
Conditions studied
- Sickle Cell Disease — all drugs for Sickle Cell Disease →
Sponsor
University of California, Irvine
Who can join
14 and older, any sex, with Sickle Cell Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multi-site, multi-visit feasibility RCT of music therapy (MT) among adolescent and adult patients (aged 14 and older) with sickle cell disease (SCD). Subjects will be randomized into one of three groups, either (1) 6 visits of in- person MT (InMT:); (2) 1 visit of in-person MT and 5 visits of virtual MT (HybMT); or (3) 1 visit of in-person health education and 5 visits of virtual health education (HybHE). Cohorts of 15 participants (10 at site 1 and 5 site 2) will be recruited each quarter for 6 quarters to reach 90 participants. Cohorts will maintain a semi-structured recruitment, consenting, assessment, and intervention schedule. The primary objective of the study is to examine the feasibility of study. This is defined by 6 metrics: (1) completeness of data collection, (2) participant screening, (3) participant recruitment, (4) participant retention, (5) Individual attendance and (6) Home practice. A final determination of "feasibility" for the study will be met if any 4 of the 6 metrics described above are met. This study will also include a secondary objective of conducting qualitative interviews to assess feasibility of implementation.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
MULTIsite feasibility of MUSIc therapy to address Quality Of Life in Sickle cell disease (MULTI-MUSIQOLS): protocol for a mixed-methods randomised controlled trial at two US medical centres.
Rodgers-Melnick SN, Gorthi V, Foss A, Erande A, et al · · 2026 · PMID 41802789 · DOI 10.1136/bmjopen-2025-115036
Verify or expand the search:
- PubMed search for NCT06853158
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Music therapy
Trials testing the same drug.
- NCT04155528 — Effect of Music Therapy on Postoperative Health Outcomes · NA · not yet recruiting
- NCT07198971 — Feasibility Study Incorporating Music Therapy to Optimise the Smoking Cessation Process Coordinated by a Tobacco Addicti · NA · recruiting
- NCT07218055 — Assessment of Music Experiences in Navigating Depression Part 2 · NA · recruiting
- NCT06995092 — Rhythmic Auditory Stimulation as Pre-Gait Training for Improving Balance and Weight Shifting in Rehabilitation Patients · NA · completed
- NCT07425847 — The Effect of Music Therapy and the 4-7-8 Breathing Exercise · NA · completed
Other recruiting trials for Sickle Cell Disease
Currently open trials in the same condition.
- NCT07369024 — Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults · Phase 2 · recruiting
- NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
- NCT06260891 — Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial · Phase 2 · recruiting
- NCT07222475 — Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease · NA · recruiting
- NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting
Other University of California, Irvine trials
Trials by the same sponsor.
- NCT06952725 — Chatbot for Online Support Groups to Treat Tobacco Addiction · NA · not yet recruiting
- NCT07167862 — Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound · Phase 4 · not yet recruiting
- NCT07527325 — Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma · Phase 2 · not yet recruiting
- NCT07391891 — Musical Mindfulness for Pain in the ED Waiting Room · NA · not yet recruiting
- NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06853158 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, Irvine
- Last refreshed: 29 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06853158.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing